Greater Cannabis Company, Inc. Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
November 08, 2021 at 06:20 pm IST
Share
Greater Cannabis Company, Inc. announced that it has begun the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The Company?s announcement of the preclinical study follows the signing of a license and research agreement with share Zedek Scientific related to the invention developed by Dr. Adi Aran, renowned cannabinoid researcher. Dr. Aran will lead the clinical study while Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, will be leading the preclinical study. The preclinical study aims to assess the synergistic impact of various combinations of the neuroprotective therapeutic in a preclinical model. Professor Burstyn-Cohen?s lab studies how microglia function in the regulation and maintenance of a healthy nervous system, and the consequences of any disruption of their function. The Company expects the study to generate in vitro data that will demonstrate significant neuroprotective attributes of the therapeutic. The study is expected to conclude by the third quarter of 2022, and the research team will produce interim evaluations of each assessment method beginning in the first quarter of 2022.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.